| Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapy | European journal of surgical oncology | | | 2026 | 15 | 146 |
|
| Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer : What have we accomplished so far ? | Cancer treatment reviews | | | 2026 | 10 | 0 |
|
| Prediction of oncogene mutation status in non-small cell lung cancer : a systematic review and meta-analysis with a special focus on artificial intelligence-based methods | European radiology | | | 2026 | 6 | 82 |
|
| Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19) | European journal of cancer | | | 2026 | 7 | 56 |
|
| Rationale and Design of the AUSTRAL trial : An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen | Clinical lung cancer | | | 2025 | 6 | 0 |
|
| Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials : results from the Pembro-real 5Y global registry | Journal for immunotherapy of cancer | | | 2025 | 80 | 76 |
|
| Acceptability of an Electronic Patient-Reported Outcomes-Based Model of Care to Monitor Symptoms Related to Cancer Treatment with Immune Checkpoint Inhibitors : Results from the IePRO Randomized Controlled Trial | Seminars in oncology nursing | | | 2025 | 9 | 78 |
|
| Targeted therapy for older patients with an oncogene driven non-small cell lung cancer : Recommendations from a SIOG expert group | Lung cancer | | | 2025 | 46 | 506 |
|
| Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC : From Bedside to Bench and Back | BioDrugs | | | 2025 | 56 | 973 |
|
| Antibody-drug conjugates in NSCLC with actionable genomic alterations : Optimizing smart delivery of chemotherapy to the target | Cancer treatment reviews | | | 2025 | 52 | 222 |
|
| Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50% : insights from the pembrolizumab 5-year global registry | Journal for immunotherapy of cancer | | | 2025 | 7 | 18 |
|
| First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC | Clinical cancer research | | | 2025 | 6 | 30 |
|
| Case Report : Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation : a case series and literature review | Frontiers in oncology | | | 2025 | 5 | 282 |
|
| First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17 | European journal of cancer | | | 2024 | 93 | 183 |
|
| Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study | The Lancet. Respiratory medicine | | | 2024 | 29 | 1 |
|
| Neoadjuvant chemo-immunotherapy for early-stage non-small cell lung cancer : a systematic review and meta-analysis | JAMA network open | | | 2024 | 98 | 118 |
|
| Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review | Journal of thoracic oncology | | | 2024 | 175 | 1,160 |
|
| Rare synchronous lung cancers in a nonsmoker with epidermal growth factor receptor and mesenchymal-epithelial transition alterations : a case report | Case reports in oncology | | | 2024 | 81 | 101 |
|
| The value of high-risk clinicopathologic features for chemotherapy in stage I non-small cell lung cancer : a propensity score-matched study | Journal of thoracic disease | | | 2024 | 98 | 127 |
|
| Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations : A Systematic Review and Single-Arm Meta-Analysis | JCO precision oncology | | | 2024 | 38 | 0 |
|
| Management of stage III non-small-cell lung cancer : rays of hope | Exploration of targeted anti-tumor therapy | | | 2024 | 77 | 253 |
|
| Mobocertinib in patients with EGFR exon 20 insertion-positive non-small cell lung cancer (MOON) : an international real-world safety and efficacy analysis | International journal of molecular sciences | | | 2024 | 113 | 20 |
|
| ADRIATIC : When face value is enough | Med | | | 2024 | 45 | 0 |
|
| Shrinking sample sizes in lung cancer trials : Various explanations, open questions | European journal of cancer | | | 2024 | 22 | 0 |
|
| Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC | The New England journal of medicine | | | 2024 | 19 | 0 |
|
| Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer | British journal of cancer | | | 2024 | 165 | 247 |
|
| Oncogenic alterations in advanced NSCLC : a molecular super-highway | Biomarker research | | | 2024 | 87 | 638 |
|
| L’immunothérapie en oncologie : entre espoirs, défis et équité | Revue médicale suisse | | | 2024 | 32 | 47 |
|
| Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC : A Brief Report | Journal of thoracic oncology | | | 2024 | 49 | 129 |
|
| Lung cancer in Switzerland | Journal of thoracic oncology | | | 2024 | 93 | 0 |
|
| Rates of febrile neutropenia and its causes in the real world | Future oncology | | | 2024 | 33 | 464 |
|
| Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer | Clinical medicine insights. Oncology | | | 2023 | 88 | 875 |
|
| Immunotherapy in non-small-cell lung cancer (NSCLC) | Praxis | | | 2023 | 66 | 0 |
|
| Safety of extended interval dosing immune checkpoint inhibitors : a multicenter cohort study | Journal of the National Cancer Institute | | | 2023 | 69 | 73 |
|
| Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer | Translational lung cancer research | | | 2023 | 106 | 68 |
|
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma | Journal of clinical medicine | | | 2023 | 54 | 152 |
|
| Testing a model of care for patients on immune checkpoint inhibitors based on electronic patient-reported outcomes : protocol for a randomized phase II controlled trial | JMIR research protocols | | | 2023 | 135 | 279 |
|
| Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study | Frontiers in oncology | | | 2023 | 118 | 126 |
|
| Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy : a Spinnaker study sub-analysis | Frontiers in oncology | | | 2023 | 86 | 47 |
|
| The effects of GCSF primary prophylaxis on survival outcomes and toxicity in patients with advanced non-small cell lung cancer on first-line chemoimmunotherapy : a sub-analysis of the spinnaker study | International journal of molecular sciences | | | 2023 | 124 | 151 |
|
| Current approaches to neoadjuvant immunotherapy in resectable non-small cell lung cancer | Current oncology reports | | | 2023 | 102 | 262 |
|
| Neoadjuvant immunotherapy : a promising new standard of care | International journal of molecular sciences | | | 2023 | 111 | 750 |
|
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | | 2023 | 108 | 127 |
|
| An optimized method to culture human primary lung tumor cell spheroids | Cancers | | | 2023 | 123 | 65 |
|
| Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14 | ESMO open | | | 2023 | 147 | 158 |
|
| Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors : An INVIDIa-2 study sub-analysis | iScience | | | 2023 | 84 | 50 |
|
| RET aberrant cancers and RET inhibitor therapies : Current state-of-the-art and future perspectives | Pharmacology & therapeutics | | | 2023 | 89 | 612 |
|
| Quality of life in the adjuvant setting : a meta-analysis of us food and drug administration approved anti-cancer drugs from 2018 to 2022 | Journal of cancer policy | | | 2023 | 71 | 35 |
|
| Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer : 2-Year Analysis of CodeBreaK 100 | Journal of clinical oncology | | | 2023 | 103 | 60 |
|
| UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN) | Journal of thoracic oncology | | | 2023 | 107 | 43 |
|
| Pleural mesothelioma in the era of immunotherapy | Clinical medicine insights. Oncology | | | 2023 | 66 | 184 |
|
| SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients | Vaccines | | | 2023 | 96 | 152 |
|
| Carrières en oncologie et leadership féminin : les progrès sont-ils au point mort ? | Revue médicale suisse | | | 2023 | 65 | 38 |
|
| Development and validation of a DNA damage repair-related gene-based prediction model for the prognosis of lung adenocarcinoma | Journal of thoracic disease | | | 2023 | 78 | 130 |
|
| Cellular therapy in NSCLC : between myth and reality | Current oncology reports | | | 2023 | 61 | 450 |
|
| Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer : A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium | Journal of clinical oncology | | | 2023 | 125 | 195 |
|
| Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study | Lung cancer | | | 2022 | 231 | 280 |
|
| Drugging KRAS : current perspectives and state-of-art review | Journal of hematology & oncology | | | 2022 | 3 | 3 |
|
| Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | | | 2022 | 245 | 199 |
|
| The Landscape of Immunotherapy Resistance in NSCLC | Frontiers in oncology | | | 2022 | 144 | 290 |
|
| Editorial: Insights in thoracic oncology: 2021/2022 | Frontiers in oncology | | | 2022 | 91 | 120 |
|
| A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial | Lung cancer | | | 2022 | 215 | 0 |
|
| Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment | Journal of clinical medicine | | | 2022 | 64 | 169 |
|
| Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study | Translational lung cancer research | | | 2022 | 64 | 112 |
|
| Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial | Cancer | | | 2022 | 273 | 602 |
|
| Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials | European journal of cancer | | | 2022 | 77 | 0 |
|
| Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis | Translational lung cancer research | | | 2022 | 67 | 83 |
|
| First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy | Frontiers in medicine | | | 2022 | 128 | 3,421 |
|
| International survey on frailty assessment in patients with cancer | The oncologist | | | 2022 | 87 | 44 |
|
| Biomarkers for checkpoint inhibitors in NSCLC | | | | 2021 | 712 | 0 |
|
| Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors : A Delphi study | European journal of cancer | | | 2021 | 6 | 95 |
|
| The impact of variant allele frequency in EGFR mutated NSCLCc patients on targeted therapy | Frontiers in Oncology | | | 2021 | 378 | 241 |
|
| Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer | Cancer Cell | | | 2021 | 298 | 425 |
|
| COVID-19 and lung cancer: risks, mechanisms and treatment interactions | Journal for immunotherapy of cancer | | | 2020 | 90 | 56 |
|
| Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer | Cancer Genomics & Proteomics | | | 2020 | 227 | 202 |
|
| Tissue-plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors | Frontiers in Oncology | | | 2020 | 300 | 317 |
|
| Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation | Gynecologic Oncology Reports | | | 2020 | 292 | 234 |
|
| Managing cancer patients during the COVID-19 pandemic : an ESMO multidisciplinary expert consensus | Annals of oncology | | | 2020 | 7 | 61 |
|
| Targeted Therapies in Early Stage NSCLC : Hype or Hope? | International journal of molecular sciences | | | 2020 | 79 | 179 |
|
| Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC | Current treatment options in oncology | | | 2019 | 3 | 11 |
|
| Prophylactic cranial irradiation in extensive disease small cell lung cancer : an endless debate | Critical reviews in oncology/hematology | | | 2019 | 78 | 0 |
|
| Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis | PLOS ONE | | | 2019 | 283 | 332 |
|
| Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era | Current oncology reports | | | 2019 | 3 | 0 |
|
| Prophylactic Cranial Irradiation in Stage III Non-Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point | Journal of Clinical Oncology | | | 2018 | 507 | 1 |
|
| Learning from the past to design better trials in second-line treatment for mesothelioma patients | Ecancermedicalscience | | | 2018 | 365 | 154 |
|
